• Publications
  • Influence
Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma
Our group recently demonstrated that autoimmune T cells directed against central nervous system-associated myelin antigens protect neurons from secondary degeneration. We further showed that theExpand
  • 290
  • 15
  • PDF
Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension.
PURPOSE To examine the neuroprotective effect of the alpha(2)-adrenergic agonist brimonidine in a chronic ocular hypertension model. METHODS Intraocular pressure (IOP) was elevated by laserExpand
  • 294
  • 13
  • PDF
RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection.
PURPOSE To establish a method for morphometric analysis of retrogradely labeled retinal ganglion cells (RGCs) of the mouse retina, to be used for the study of molecular aspects of RGC survival andExpand
  • 162
  • 8
  • PDF
Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat
Alpha-2 adrenoceptor agonists have previously been shown to enhance neuronal survival in an optic nerve mechanical injury model and to protect photoreceptors in a light-induced degeneration model.Expand
  • 87
  • 8
alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia.
Recent studies have suggested that alpha(2)-adrenergic agonists prevent neuronal cell death in a number of animal models, although the mechanism of alpha(2)-neuroprotection remains unclear. In aExpand
  • 132
  • 7
  • PDF
Glaucoma Alters the Circadian Timing System
Glaucoma is a widespread ocular disease and major cause of blindness characterized by progressive, irreversible damage of the optic nerve. Although the degenerative loss of retinal ganglion cellsExpand
  • 122
  • 6
  • PDF
Role of alpha-2 agonists in neuroprotection.
Four criteria are used to evaluate the potential usefulness of an agent for neuroprotection in glaucoma: 1) the agent must have a target in the retina; 2) it must be neuroprotective in animal models;Expand
  • 107
  • 5
Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.
PURPOSE alpha2 Agonists, such as brimonidine, have been shown to protect retinal ganglion cells (RGCs) in animal models of glaucoma and acute retinal ischemia. In this study, the authors investigatedExpand
  • 126
  • 5
  • PDF
Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma.
The loss of retinal ganglion cells (RGCs) in glaucoma occurs progressively over many years. A neuroprotective drug should enhance survival of RGCs in the presence of chronic stress/injury. FourExpand
  • 96
  • 5